We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cronos Group (CRON - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cronos Group is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRON's full-year earnings has moved 200% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CRON has returned 27.4% so far this year. Meanwhile, stocks in the Medical group have gained about 6.3% on average. This shows that Cronos Group is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Amgen (AMGN - Free Report) . The stock has returned 34.2% year-to-date.
In Amgen's case, the consensus EPS estimate for the current year increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Cronos Group is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 2.1% this year, meaning that CRON is performing better in terms of year-to-date returns.
On the other hand, Amgen belongs to the Medical - Biomedical and Genetics industry. This 449-stock industry is currently ranked #100. The industry has moved +5.9% year to date.
Cronos Group and Amgen could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cronos Group (CRON - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cronos Group is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRON's full-year earnings has moved 200% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CRON has returned 27.4% so far this year. Meanwhile, stocks in the Medical group have gained about 6.3% on average. This shows that Cronos Group is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Amgen (AMGN - Free Report) . The stock has returned 34.2% year-to-date.
In Amgen's case, the consensus EPS estimate for the current year increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Cronos Group is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 2.1% this year, meaning that CRON is performing better in terms of year-to-date returns.
On the other hand, Amgen belongs to the Medical - Biomedical and Genetics industry. This 449-stock industry is currently ranked #100. The industry has moved +5.9% year to date.
Cronos Group and Amgen could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.